X
[{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Junshi Biosciences"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Biosimilar of adalimumab (UBP 1211) is recombinant humanised anti -tumour necrosis factor alpha (TNF-alpha) mAB, for treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children.
Lead Product(s):
Adalimumab
Therapeutic Area: Gastroenterology
Product Name: UBP1211
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 17, 2022
Details:
The results of the completed phase II clinical trial showed that Anaprazole is effective in treating duodenal ulcer, conducive to ulcer healing and relieves ulcer-related symptoms.
Lead Product(s):
Anaprazole sodium
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 14, 2020